Raise your hand if you’ve ever said, “I’d try hormones, but don’t they cause cancer?” 🙋♀️
Girl, you are not alone. That one fear has kept a whole generation of women sweating through meetings, lying awake at 3 a.m. and white-knuckling perimenopause, all because of headlines from 2002.
So let’s do this properly: what the research actually says, what changed (spoiler: a lot), and who hormone therapy is and isn’t a good fit for. Sources are numbered at the bottom, as always. 🤓
The 10-second answer: For most healthy women who start hormone therapy before 60, or within 10 years of their last period, the benefits outweigh the risks [1]. In late 2025 the FDA began removing the scary “black box” warnings about heart disease, breast cancer and dementia from hormone therapy labels [2, 3]. It’s not risk-free, and it’s not for everyone, but it’s a lot safer than you were told.
So why was everyone so scared? (A quick 2002 flashback)
In 2002, a huge study called the Women’s Health Initiative (WHI) made headlines suggesting hormone therapy raised the risk of breast cancer, heart disease and stroke. Practically overnight, millions of women stopped their hormones and a lot of providers stopped prescribing them. 😬
Here’s the plot twist: the average woman in that study was 63 years old, many of them more than a decade past menopause, and they were taking older-style pills at higher doses than most women use today [4]. That’s very different from a 47-year-old in perimenopause starting a low-dose patch.
When researchers followed those same women for about 18 years, hormone therapy did not increase the risk of dying from any cause, heart disease or cancer. And women who started in their 50s actually had lower death rates than women on placebo [4].
Translation: the study that scared everyone mostly looked at the wrong age group. 💅🏼
Okay, but what about breast cancer?
This is the big one, so let’s get specific, because the answer depends on which hormones:
Estrogen alone (for women who’ve had a hysterectomy): in the long-term WHI follow-up, it was linked to fewer breast cancers and fewer breast cancer deaths than placebo [5]. Yes, really.
Estrogen plus a progestogen (for women who still have a uterus): linked to a small increase in breast cancer risk [5]. How small? Less than one extra case per 1,000 women per year of use [1].
For perspective, that’s a smaller risk than some everyday things like drinking alcohol regularly or carrying extra weight after menopause [1]. Your personal and family history matter a lot here, which is exactly why this conversation belongs in an exam room, not a comment section.
What about blood clots and strokes?
This is a real risk, and it’s one where how you take estrogen matters. Estrogen pills are processed by the liver, which can raise clotting risk. Estrogen through the skin (a patch, gel or spray) has not been linked to the same increase in blood clots in large studies [6].
That’s one reason I often talk with patients about skin-based options. Same hormone, different route, different risk profile. 🧠
What the FDA changed (the big news)
In November 2025, the FDA announced it would remove the boxed warnings about heart disease, breast cancer and probable dementia from menopausal hormone therapy labels [2]. In February 2026, the first six products got updated labels [3], and more have followed since, including some estradiol patches in October 2026 [7].
A couple of important details:
The boxed warning about endometrial (uterine) cancer stays on systemic estrogen-only products [2]. That’s why women who still have a uterus take a progestogen along with estrogen: it protects the uterine lining.
The FDA’s guidance is to start systemic hormone therapy within 10 years of menopause or before age 60, and to decide on timing and length of use together with your provider [2].
What hormone therapy can actually do for you
Hot flashes and night sweats: hormone therapy is the most effective treatment we have [1].
Bones: it helps prevent bone loss and fractures [1].
Vaginal dryness and pain with sex: low-dose vaginal estrogen treats these directly [1].
Sleep: fewer night sweats often means more sleep. Revolutionary, I know. 😴
Who may NOT be a good fit (no jokes here)
Hormone therapy usually isn’t recommended if you have a history of breast cancer, a prior blood clot or stroke, heart disease, active liver disease, or unexplained vaginal bleeding [1].
That said, these aren’t automatic dead ends. If you have any of these conditions and you’re interested in hormone therapy, talk with your provider about your options. Some women still choose hormone therapy after carefully weighing their personal risks and benefits with their care team. And if hormones aren’t right for you, there are effective non-hormone prescriptions for hot flashes too [8].
The bottom line
Hormone therapy isn’t a scary last resort, and it isn’t a magic potion either. It’s a medical treatment with real benefits and real risks, and the right answer depends on your age, your symptoms, your health history and your goals.
My job is to walk through all of that with you, honestly, so you can make the call that’s right for you.
Let’s talk about it
I’m Dr. Abigail Prushansky, DNP, APRN, FNP-BC, CNM, and I help women weigh their hormone therapy options every week. Visits are in person at my Torrance office or by video visit anywhere in California. We accept most major insurance plans (contact us to verify yours). Serving Los Angeles, the South Bay, the Westside and Beverly Hills.
Want a plan you can start on today? My Perimenopause Roadmap + Toolkit is a clinician-designed guide to what’s happening in your body during perimenopause, with practical tools to help you take the next step. 📚
Learn more about perimenopause and menopause care →
Not sure if you’re in perimenopause or menopause? Start here →
And if your friend is still scared of hormones because of a headline from 2002? Send her this. ❤️
This article is for education and isn’t medical advice for you specifically. For that, come see me (or your own provider) before starting or changing any treatment. 😉
Sources
The North American Menopause Society. The 2022 hormone therapy position statement. Menopause. 2022;29(7):767–794. PubMed
U.S. Department of Health and Human Services. Fact sheet: FDA initiates removal of “black box” warnings from menopausal hormone replacement therapy products. November 10, 2025. hhs.gov
U.S. Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. February 12, 2026. fda.gov
Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927–938. PubMed
Chlebowski RT, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. 2020;324(4):369–380. jamanetwork.com
Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. doi:10.1136/bmj.k4810
Contemporary OB/GYN. FDA removes boxed warnings from 3 more menopausal hormone therapy products. October 30, 2026. contemporaryobgyn.net
The North American Menopause Society. The 2023 nonhormone therapy position statement. Menopause. 2023;30(6):573–590. doi:10.1097/GME.0000000000002200